Abstract: Pharmaceutical compositions comprising eutectic mixtures comprising Cannabidiol (CBD) and at least one physiologically acceptable organic compound, allowing to increase solubility of cannabinoid in pharmaceutical compositions and to improve drug loading, drug absorption and bioavailability of CBD after administration.

Abstract: Methods and systems for generating voices based on characteristics of an avatar. One or more characteristics of an avatar are obtained and one or more parameters of a voice synthesizer for generating a voice corresponding to the one or more avatar characteristics are determined. The voice synthesizer is configured based on the one or more parameters and a voice is generated using the parameterized voice synthesizer.

Abstract: Methods and systems for generating voices based on characteristics of an avatar. One or more characteristics of an avatar are obtained and one or more parameters of a voice synthesizer for generating a voice corresponding to the one or more avatar characteristics are determined. The voice synthesizer is configured based on the one or more parameters and a voice is generated using the parameterized voice synthesizer.

Abstract: The invention relates to pharmaceutical compositions based on a menthyl ester of indomethacin, which may be used as anti-inflammatory drugs to treat acute and chronic inflammatory diseases. The aforementioned pharmaceutical compositions have anti-inflammatory, analgesic and antipyretic action and don't have adverse ulcerogenic action in therapeutic doses. 1 independent claim, 7 tables, 1 figure, 13 examples.

Abstract: The present disclosure relates to pharmaceutical compositions of solid dosage form for intraoral administration that provides effective delivery of insulin and insulin analogs via the transmucosal route. Also provided are methods for treating pre-diabetes, diabetes and metabolic syndrome in a subject in need thereof.

Abstract: The present disclosure relates to a method of preparation of beverages, containing poorly water soluble cannabinoids, by two-stage dilution of the self-nanoemulsifying concentrate, and composition of the concentrate for preparation of such beverages.

Abstract: The present disclosure relates to self-emulsifying pharmaceutical compositions for transmucosal delivery of biologically active peptides and proteins.

Abstract: The present disclosure relates to self-emulsifying oral compositions for enhanced absorption of poorly water soluble triterpenes, such as pentacyclic triterpene acids, either in substantially pure form or as a constituents of herbal extracts.

Abstract: The current application relates to a liquid pharmaceutical composition for intraoral transmucosal administration of a benzodiazepine drug to a mammal. The composition comprises a physiologically acceptable hydrophobic phase, an eutectic mixture of benzodiazepine compound providing high solubility of the benzodiazepine in said hydrophobic phase, at least one physiologically acceptable organic solvent and at least one physiologically acceptable surfactant.

Abstract: The current application relates to a liquid pharmaceutical composition for intiaoral transmucosal administration of a benzodiazepine drag to a mammal The composition comprises a physiologically acceptable hydrophobic phase, a eutectic mixture of benzodiazepine compound providing high solubility of the benzodiazepine in said hydrophobic phase, at least one physiologically acceptable organic solvent and at least one physiologically acceptable surfactant.

Abstract: The present disclosure relates to pharmaceutical compositions of solid dosage form for intraoral administration that provides effective delivery of insulin and insulin analogs via the transmucosal route. Also provided are methods for treating pre-diabetes, diabetes and metabolic syndrome in a subject in need thereof.

Abstract: The invention describes medicinal compositions, comprising combination of essential oils, and method for treatment of cystitis and urinary tract infections by oral administration of such compositions.

Abstract: There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.

Abstract: There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.

Abstract: The invention relates to a sustained release pharmaceutical composition, containing mebicar, for the treatment of anxiety, depression and other psychiatric and neurological disorders.

Abstract: A multiple-component sensor film includes a carrier polymer matrix and film reactants dispersed within the carrier polymer matrix. The carrier polymer matrix includes a carrier polymer, which includes hydroxypropyl cellulose polymer and the film reactants include an indicator and a reactant from the group of a buffer, a stabilizer, a masking agent, a solubilizer and an internal reference dye. Methods for making the multiple-component sensor film and methods for monitoring the concentration of water soluble polymers in aqueous media are also provided.

Abstract: The invention describes the use of an injectable form of Idebenone to protect against hepatic damage, improve recovery from liver trauma, poisoning, vapor intoxication, degenerative diseases, hepatocyte function loss and pathology associated with inflammation or infection. The use of injectable Idebenone restores liver function, suppresses elevated enzyme levels, decreases alcoholic and drug abuse associated syndromes, symptoms of acute hepatitis of various origins, the consequences of liver reperfusion and other signs of liver damage.

Abstract: A vehicle for topical delivery which contains a liquid eutectic mixture of hydrophobic compounds.

Abstract: Provided is a set of two or more mass labels, each label in the set comprising a mass marker moiety attached via a cleavable linker having at least one amide bond to a mass normalization moiety, wherein the aggregate mass of each label in the set may be the same or different and the mass of the mass marker moiety of each label in the set may be the same or different, and wherein in any group of labels within the set having a mass marker moiety of a common mass each label has an aggregate mass different from all other labels in that group, and wherein in any group of labels within the set having a common aggregate mass each label has a mass marker moiety having a mass different from that of all other mass marker moieties in that group, such that all of the mass labels in the set are distinguishable from each other by mass spectrometry, and wherein the mass marker moiety comprises an amino acid and the mass normalization moiety comprises an amino acid.

Abstract: The invention describes use of an injectable form of Idebenone, suitable for intravenous injection or infusion. The proposed formulation is an oil-in-water emulsion, where Idebenone is associated with the oil droplets.